NHSL3 and breast carcinoma: Nevertheless, our findings suggested that circAAGAB inhibited breast cancer progression through the circAAGAB-miR-378 h-KIAA1522/NKX3-1/JADE3 axis and could serve as a novel biomarker or target for therapy.